Transkaryotic Therapies

This article or the following section is not adequately provided with supporting documents ( e.g. individual evidence ). Information without sufficient evidence could be removed soon. Please help Wikipedia by researching the information and including good evidence.

Transkaryotic Therapies
legal form	Corporation
founding	1988
resolution	2005
Reason for dissolution	Takeover by Shire
Seat	Cambridge , United States
management	Michael Astrue
Branch	Biotech

Transkaryotic Therapies was a US biopharmaceutical company founded in 1988 with headquarters in Cambridge , Massachusetts and additional offices in Europe , Canada and South America .

The company had specialized in the research, development and marketing of therapies for diseases caused by protein deficiency. The product portfolio included Replagal ^® , which is used in the treatment of Fabry's disease . Therapies for the treatment of type II mucopolysaccharidosis ( Hunter's disease ) and Gaucher's disease were also in the development phase.

In cooperation with Sanofi-Aventis and Lonza , TKT developed the product DynEpo ^® , an erythropoietin derivative for the treatment of anemia , which is generated in transformed human cells using patented gene activation technology. Approval for the European market has been in place since March 18, 2002.

In 2005, TKT was taken over by the British pharmaceutical company Shire Pharmaceuticals .

Individual evidence

1. ↑ UK drug maker agrees to buy Transkaryotic , at www.readabstracts.com , accessed February 4, 2017